GPCR
Structure Therapeutics Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Mar 16 ▲ Structure Therapeutics announced positive Phase 2 results for alenig…
- Apr 14 ▼ 1 insider sell $961.1K at $55.07
- Apr 27 FDA: Structure Therapeutics to Present Aleniglipron, Amylin and…
- May 7 Structure Therapeutics reported Q1 2026 net loss of $76.0M, widening…
- Jun 5 FDA: Structure Therapeutics Announces Publication in Nature Med…
- Jun 25 ▼ 1 insider sell $386.6K at $49.08
- Jul 14 ▼ 1 insider sell $401.6K at $50.98
- Jul 22 ▼ 1 insider sell $873.8K at $50.07
- Aug 4 ▼ 1 insider sell $194.8K at $49.44
- Aug 18 ▼ 1 insider sell $210.6K at $53.47
- Sep 1 ▼ 1 insider sell $278.7K at $46.92
- Sep 21 ▼ 1 insider sell $144.9K at $36.15
Signal stack
Where each data set points today.
- InsidersBEARISH
3 insiders sold $3.5M.
- InstitutionsMIXED
Q3 2026: 17 added (0 new), 23 trimmed or exited.
- AnalystsBULLISH
21 of 23 rate it Buy or better. Every target is above the price.
- EstimatesFALLING
Current-quarter EPS estimate −$0.187 → −$0.241 over 90 days. 0 up, 1 down in 30 days.
- Short sellersCOVERING
Short interest −17.1% to 5.93M shares. 6.5 days to cover, ≈8.3% of shares.
- TrendDOWNTREND
32% below its 50-day average. New closing low $18.57 on Nov 16.
- SocialQUIET
No Reddit mentions this week. Last mention Nov 8.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| PRINCIPAL FINANCIAL GROUP INC | TRIM | $39.6M |
| Aberdeen Group plc | ADD | $26.9M |
| BlackRock, Inc. | ADD | $22.1M |
| JPMORGAN CHASE & CO | DOUBLED | $17.9M |
| AMERICAN CENTURY COMPANIES INC | NEAR_EXIT | $9.5M |
| FRANKLIN TEMPLETON INC | TRIM | $7.6M |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | TRIM | $4.2M |
| MARSHALL WACE, LLP | TRIM | $3.4M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
23 analystsPrice is below the lowest target. Median implies +441%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Sep 9, 2026 | Citizens REITERATE | Market Outperform |
| Aug 7, 2026 | Citigroup MAINTAIN | Buy |
| Aug 7, 2026 | Citizens MAINTAIN | Market Outperform |
| Jun 11, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Coll Crespo Blas CHIEF MEDICAL OFFICER Sep 21, 2026 | CONVERT | 12,024 sh |
Coll Crespo Blas CHIEF MEDICAL OFFICER Sep 21, 2026 | CONVERT | 4,008 sh |
Coll Crespo Blas CHIEF MEDICAL OFFICER Sep 21, 2026 | SELL | $144.9K |
Coll Crespo Blas CHIEF MEDICAL OFFICER Sep 18, 2026 | TAX W/H | $124.0K |
Lin Xichen CHIEF SCIENTIFIC OFFICER Sep 1, 2026 | SELL | $4.8K |
Lin Xichen CHIEF SCIENTIFIC OFFICER Sep 1, 2026 | SELL | $59.6K |
Lin Xichen CHIEF SCIENTIFIC OFFICER Sep 1, 2026 | SELL | $214.3K |
Lin Xichen CHIEF SCIENTIFIC OFFICER Sep 1, 2026 | CONVERT | 17,817 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.24 | -$0.57–$2.02 | -3.4% | $0.00 |
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
8 filings · 2 press releases · 0 bullish · 1 bearish · 2 mixed · 5 neutral- NEUTRAL SC 13G/ANov 16, 2026
Wellington Management Group LLP filed an amended Schedule 13G reporting a 13.6% passive stake in Structure Therapeutics Inc. (GPCR) as of September 30, 2026, up from a prior 12.8% reported by Wellington Management Company LLP. The increase reflects continued accumulation by a major institutional…
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL SC 13G/ANov 16, 2026
Deep Track Capital, LP filed an amended Schedule 13G reporting a new 7.18% passive stake in Structure Therapeutics Inc. (GPCR) as of September 30, 2026, consisting of 15,000,000 common shares (including 5,000,000 ADSs). This is a new disclosure from Deep Track, which was not previously a reported…
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL PRESS-RELEASENov 9, 2026
Structure Therapeutics reported Q3 2026 net loss of $144.8M, wider than the $65.7M loss in Q3…
Watch for aleniglipron body composition, T2DM and SWITCH data expected in Q4 2026, which could de-risk the Phase 3 program. ACCG-2671 MAD data in 1H 2027 is the next major pipeline catalyst.
- NEUTRAL SC 13G/ANov 5, 2026
FMR LLC (Fidelity) filed an amended Schedule 13G reporting beneficial ownership of 32,089,434…
Fidelity's passive stake remains unchanged at 15.0%, indicating no material conviction shift. Monitor next 13F filing for any position changes and watch for any conversion to 13D if Fidelity's…
All GPCR filing & press-release reports (10)
- SC 13G/A reportNov 16, 2026
- SC 13G/A reportNov 16, 2026
- PRESS-RELEASE reportNov 9, 2026
- SC 13G/A reportNov 5, 2026
- INST-CLUSTER reportJun 11, 2026
- 8-K reportMay 7, 2026
- PRESS-RELEASE reportApr 27, 2026
- 8-K reportApr 15, 2026
- PRESS-RELEASE reportMar 16, 2026
- INST-CLUSTER reportFeb 28, 2026